Eli Lilly Reports Record Q1 Revenue but Faces Profit Pressure and Competitive Challenges

The pharmaceutical giant's diabetes and obesity drugs fueled a 45% revenue surge, but profit guidance was cut due to acquisition costs and CVS's formulary change.